Literature DB >> 22736017

Understanding the role of PNPLA3 genetic variants in patients with chronic hepatitis C infection.

Alessio Aghemo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22736017     DOI： 10.1007/s10620-012-2277-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  24 in total

1.  I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Anna Alisi; Enrico Galmozzi; Andrea Bartuli; Benedetta Del Menico; Arianna Alterio; Paola Dongiovanni; Silvia Fargion; Valerio Nobili
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma.

Authors:  Stefano Ginanni Corradini; Maria Antonella Burza; Antonio Molinaro; Stefano Romeo
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

4.  Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Keyur Patel; Hans L Tillmann; Paul J Clark; Susanna Naggie; Jacques Fellay; Dongliang Ge; Jeanette J McCarthy; David B Goldstein; John G McHutchison
Journal:  Hepatology       Date:  2010-06-30       Impact factor: 17.425

5.  Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.

Authors:  José Velosa; Fátima Serejo; Rui Marinho; Joana Nunes; Helena Glória
Journal:  Dig Dis Sci       Date:  2011-03-05       Impact factor: 3.199

Review 6.  Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

Review 7.  Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

Authors:  Alessio Aghemo; Pietro Lampertico; Massimo Colombo
Journal:  J Hepatol       Date:  2012-06-28       Impact factor: 25.083

8.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

Authors:  Laetitia Fartoux; Olivier Chazouillères; Dominique Wendum; Raoul Poupon; Lawrence Serfaty
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

Review 9.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

10.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425
View more
  1 in total

Review 1.  Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation.

Authors:  Ning Geng; Yong-Ning Xin; Harry Hua-Xiang Xia; Man Jiang; Jian Wang; Yang Liu; Li-Zhen Chen; Shi-Ying Xuan
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.